Tolero Pharmaceuticals Home
Making Meaningful Medicines
Tolero Pharmaceuticals, Inc.,
a clinical-stage company, is developing treatments to improve and extend the lives of patients with serious hematological diseases.
clear space
Tolero Pharmaceuticals Closes $14.2 Million Series B Financing Line Tolero Pharmaceuticals, Inc. Presents Positive Interim Phase 2 Clinical Trial Results of Alvocidib for the Treatment of Front Line AML at 2014 ASCO Annual Meeting Line Tolero Pharmaceuticals Receives FDA Orphan Drug Designation for Alvocidib for the Treatment of Acute Myeloid Leukemia

Tolero Pharmaceuticals

Tolero PharmaceuticalsTolero Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to alleviating human suffering through the discovery and development of novel therapeutics to treat cancer and other serious human diseases. Our pipeline targets important biological drivers of blood disorders to treat leukemias and anemia. MORE
Researchers
Learn how Tolero researchers are actively expanding scientific understanding of hematological disease. MORE
Patients
See how clinical trials on the use of Alvocidib to treat acute myeloid leukemia (AML) are demonstrating promising results. MORE
Investors
Find out how Tolero's pipeline agents offer tremendous opportunities for investors. MORE
clear space